<i>In Vivo</i> Evolution of GES β-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections
Pablo A. Fraile-Ribot, Javier Fernández, María A. Gomis-Font, L. Forcelledo, Xavier Mulet, Carla López-Causapé, Antonio Oliver
Abstract
The mechanisms underlying an in vivo switch in the resistance phenotype of P. aeruginosa after ceftazidime-avibactam treatment was investigated. The initial isolate (a blood culture) was resistant to meropenem but remained susceptible to antipseudomonal cephalosporins and combinations with β-lactamase inhibitors.
Topics & Concepts
Ceftazidime/avibactamPseudomonas aeruginosaCeftazidimeIn vivoMicrobiologyAvibactamBiologyMedicineBacteriaGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance